Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 71 results found. Search for [ covishield ]

Results 1 to 21 of 71
PTI
December 1, 2020
A 40-year-old man who was a volunteer in the third phase of the ''Covidshield'' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions


BusinessToday.In
December 1, 2020
Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), said that the primary objective of vaccination is to break the COVID-19 transmission chain


BusinessToday.In
December 1, 2020
The plans offer coverage under two different conditions, the first being one where job/income is lost due to termination/lay-off or retrenchment, and the second condition is where job/income is lost due to disability or death


BusinessToday.In
December 1, 2020
Justin Trudeau's comment has not gone well with both the ruling Bharatiya Janata Party and Aam Aadmi Party. External Affairs Ministry Spokesperson Anurag Srivastava called Trudeau's remarks as 'ill-informed' and 'unwarranted'


BusinessToday.In
December 1, 2020
The trial will run for 12 months until December next year. Unilever said the employees will be paid for five days while working for just four days


BusinessToday.In
December 1, 2020
In a statement, SII said the incident with the Chennai volunteer, though highly unfortunate, was in no way induced by the vaccine and that SII is sympathetic with the volunteer's medical condition


BusinessToday.In
November 29, 2020
A 40-year-old Chennai-based man had alleged that he suffered serious side effects following vaccination and sought Rs 5 crore compensation in a legal notice to Serum Institute and others, besides seeking a halt to the trial


PTI
November 29, 2020
The legal notice has been sent to Pune based Serum Institute of India, which has collaborated with Oxford University and Astra Zeneca, a pharmaceutical company, in connection with making of the vaccine, 'Covidshield.'


BusinessToday.In
November 29, 2020
Poonawallathanks PM Modi for visiting the institute; says SII shares his vision and continues to work towards ensuring a safe and secure India. SII may apply for emergency use authorisation of its vaccine in the next two weeks


BusinessToday.In
November 29, 2020
Serum Institute of India's (SII) CEO Adar Poonawalla made the announcement hours after a meeting with Prime Minister Narendra Modi, who visited Serum's plant in Pune on Saturday, November 28


PB Jayakumar
November 28, 2020
Serum Institute will have a capacity to make over 2.5 billion doses of vaccines a year as it is currently upscaling the capacity from over 1.6 billion doses  


PB Jayakumar
November 28, 2020
Prime Minister Narendra Modi's visit to these facilities and discussions with the scientists are to help him get a first-hand perspective of the preparations, challenges and roadmap in India's vaccination plans


BusinessToday.In
November 27, 2020
The company could be looking at manufacturing 100 million doses to begin with, as per Chairman Pankaj Patel.


BusinessToday.In
November 26, 2020
SII has partnered with AstraZeneca and Oxford University for the manufacturing and distribution of its COVID-19 vaccine candidate 'Covishield' in India and other countries


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
The world of vaccine and drug development is being reset. Here's how Indian pharma must reinvent to lead the new era of drug discovery and research


PB Jayakumar & Joe C Mathew
New Delhi, November 25, 2020
A blow-by-blow account of how Indian vaccines are being readied


BusinessToday.In
November 24, 2020
Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first


BusinessToday.In
November 24, 2020
Serum Institute has tied up with British-Swedish pharmaceutical firm AstraZeneca and the University of Oxford to mass-produce the Covishield vaccine to fight back COVID-19 virus


BusinessToday.In
November 23, 2020
Indian Council of Medical Research is working closely with SII for Covishield vaccine trials across 15 centres in India, and would also be funding the clinical trials in the country.


BusinessToday.In
November 23, 2020
Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection


PAGES 1 OF 4  1234